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In total, 70 patients were enrolled into this phase II study, to evaluate the activity of the pegylated liposomal doxorubicin (PLD) and
gemcitabine (GEM) combination in recurrent ovarian cancer patients. PLD, 30mgm
 2, was administered on day 1 by 600 i.v. infusion,
followed by GEM, 1000mgm
 2, given by 300 i.v. on days 1 and 8; cycles were repeated every 21 days. In all, 67 patients are so far
evaluable for response. Seven complete responses (10.4%, 95% CI: 3.1–17.7), 16 partial responses (23.9%, 95% CI: 13.7–34.1), 26
disease stabilisations (38.8%, 95% CI: 27.1–50.5) and 18 progressions (26.9%, 95% CI: 16.3–37.5) have been registered. Within the
resistant population (n¼36), the response rate was 25% (95% CI: 10.9–39.1). Within the group of platinum-sensitive patients
(n¼31), the response rate was 45.2% (95% CI: 27.7–62.7). A total of 443 courses are evaluable for toxicity. Grade 3–4
hematological toxicity was registered in 30 patients (42.8%), mainly represented by neutropenia (35.6%); palmar-plantar
erythrodysesthesia affected 24 patients (34.2%), but it was of grade 3 in only seven of them (10%).
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Over the last decade, the improvement of cytoreductive surgical
efforts and the introduction of paclitaxel in the upfront platinum-
based chemotherapy have increased the progression-free and
overall survival of ovarian cancer patients (Berek et al, 1999).
However, the recurrence of disease remains the main problem
of ovarian cancer management, since most patients still die from
the disease within 5 years of their initial diagnosis (Jemal et al,
2003).
With the exception of patients with long treatment-free intervals
who can benefit from a platinum rechallenge and have a better
prognosis (Markman et al, 1991; Ozols, 2000), for the vast majority
of recurring ovarian cancer patients, palliation is the real goal of
the second line therapy (Ozols, 2002a), in spite of the great amount
of new drugs with significant activity which have been identified in
recent years (Ozols, 1997, 2002b). In fact, the largest trials that
have recently tested the most promising new drugs such as
paclitaxel, topotecan, etoposide, liposomal doxorubicin and
gemcitabine, in relapsed ovarian cancer, have demonstrated
response rates ranging from 10 to 30% (Ten Bokkel Huinink
et al, 1997; Rose et al, 1998; Gordon et al, 2001; Markman 2002).
The use of drug combinations, which are considered a gold
standard in the first-line approach (Berek et al, 1999; Ozols, 2000),
is usually discouraged in the recurrent setting because of higher
toxicity, and the lack of any evidence of benefit in terms of survival
(Sabbatini et al, 1998; Colombo et al, 1999); nevertheless, the better
toxicity profile expressed by some new categories of drugs allows
the hypothesis that the rationalised choice of drugs with different
mechanisms of action and toxicity patterns might increase the
chances of response and favourably affect the clinical outcome. In
this context, the combination of two of the above-mentioned
drugs, namely GEM and PLD seemed particularly intriguing for
several reasons: (i) both the drugs have shown activity in ovarian
cancer (Hansen et al, 1999; Gordon et al, 2000, 2001; Markman,
2002); (ii) their different mechanisms of action are likely to
hamper a cross resistance; (iii) the combination of GEM and
doxorubicin has been reported to result in synergistic antiproli-
ferative activity in vitro (Zoli et al, 1999; Chow et al, 2000);
(iv) finally, the nonoverlapping toxicity profiles of GEM and
PLD warrant the analysis of their combination in the clinical
setting.
On the basis of the above considerations, we recently published
the results of a phase I study aimed at determining the maximum
tolerated doses (MTD) and toxicity of the GEM–PLD combination
(D’Agostino et al, 2002a). The MTD was reached at the doses of
PLD, 30mgm
 2, and GEM, 1000mgm
 2, the DLT being repre-
sented by febrile neutropenia and thrombocytopenia. In the small
subset of patients enrolled in the phase I, a response rate of 21%
was registered, which seemed to us quite encouraging considering
that the majority of those patients were undertreated as often
happens in phase I studies which do not allow an intraindividual
dose escalation (Mathe and Reizenstein, 1986). These findings
prompted us to accomplish this phase II study, in order to confirm
the promising trend in a wider subset of recurrent ovarian cancer
patients treated at the MTD, and to assess also the safety of the
treatment in terms of haematological and nonhaematological
toxicity. Received 24 March 2003; revised 20 June 2003; accepted 21 July 2003
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lMATERIALS AND METHODS
Eligibility
Patients with progressing/recurring epithelial ovarian cancer,
previously treated with at least one platinum/paclitaxel chemother-
apy regimen, and with radiological evidence of measurable
(42cm) lesions were eligible for the study. Further entry criteria
were: age over 18 years, Eastern Cooperative Oncology Group
(ECOG) performance status p2 (Oken et al, 1982), life expectancy
412 weeks, absolute neutrophil count (ANC) 41.5 10
9l
 1;
platelet count 4150 10
9l
 1; bilirubin and creatinine levels less
than 1.5 times the upper limit of normal; normal cardiac function
defined as LVEF X50%. Patients were ineligible in the case of:
previous or current malignancies at other sites with the exception
of basal or squamous cell carcinoma of the skin and cone biopsed
carcinoma in situ of the uterine cervix; Brenner’s and borderline
ovarian tumors; prior GEM or PLD chemotherapy or anthracycline
therapy with a cumulative doxorubicin dose exceeding 300mgm
 2
or a cumulative epirubicin dose exceeding 540mgm
 2; significant
heart disease including any history of ischaemic heart disease, any
history of arrhythmia requiring treatment, or clinically significant
valvular disease; other investigational cytotoxic drugs given within
30 days prior to entry into the study; symptomatic CNS metastases;
uncontrolled severe infection and/or medical problems unrelated
to malignancy which would limit full compliance with the study or
expose the patient to extreme risk.
Study design
This was a noncomparative phase II study of the combination of
PLD and GEM. The approval of the local ethic committee
was obtained prior to start of the trial. Before study entry, a
written informed consent was requested from all patients. Within
14 days from the beginning of the study treatment, patients were
submitted to a complete clinical evaluation (including CT-scan),
laboratory tests, with complete blood cell count, serum chemistry,
Ca 125 level and urinalysis, and echocardiography for the
assessment of the baseline left-ventricle ejection fraction
(LVEF).
PLD, 30mgm
 2, was administered on day 1 by 600 i.v. infusion,
followed by GEM, 1000mgm
 2, given by 300 i.v. on days 1 and 8;
cycles were repeated every 21 days. All patients received an
antiemetic prophylaxis (metoclopramide) prior to the application
of chemotherapy. Complete blood count and platelets were
performed on a weekly basis; a routine 12-channel biochemistry
was performed on days 1 and 14 of each cycle, unless differently
indicated clinically. LVEF was evaluated every two cycles of
chemotherapy by echocardiography. A multigated angiogram
(MUGA) was planned if the echocardiography registered an LVEF
decrease of 410%. Chemotherapy-induced toxicity was graded
according to the National Cancer Institute common toxicity
criteria (NCI-CTC, 1998). In the case of haemoglobin o 9gdl
 1,
ANC o 1000ml
 1 and/or PLT o 100000ml
 1, day-8 GEM
administration was dropped or day-1 PLD/GEM treatment
postponed by 1 week. In patients who had delayed treatment for
more than 2 weeks and in the case of development of
hypersensitivity reactions, treatment was discontinued. In the
presence of grade 4 haematological toxicity, the doses of GEM and
PLD were reduced by 20% in the next cycle. In the case of hand–
foot syndrome (PPE), the dose of PLD was reduced by 20% in the
next cycles. GSF and/or epoetin were administered in the cases of
haematological toxicity according to the ASCO guidelines (Ozer
et al, 2000; Rizzo et al, 2002).
Ca 125 levels were tested on day 1 of each cycle, clinical
evaluation (including CT-scan) was planned every two cycles, and
the clinical response assessed according to the RECIST criteria
(Therasse et al, 2000).
RESULTS
Patient characteristics
From December 2000 to February 2003, 70 patients were enrolled
into this phase II study. Patient characteristics are detailed in
Table 1. The median age was 59 years (range 25–76).
In all, 38 patients were considered platinum resistant, that is,
progressing during or within 6 months from the end of primary
treatment with carboplatin and paclitaxel (or platinum rechal-
lenge). A total of 32 patients were considered platinum sensitive
since they had previously responded to platinum-based
therapy and recurred more than 6 months after that treatment.
Platinum rechallenge (10 patients, 31.2%) before the enrollment
into this study was offered to those patients who relapsed
more than 12 months after the completion of primary
treatment. The median platinum-free interval was 3 months (mean
3 months, range 1–6) for the platinum-resistant patients, and 9
months (mean 13 months, range 7–39) for the platinum-sensitive
patients.
Response
In total, 67 patients are so far evaluable for response (95.7%,
Table 2). Of them, two patients died due to the early progression of
the disease after only one cycle, and one patient, previously
rechallenged with carboplatin, experienced thrombocytopenia
persisting for more than 2 weeks after the first cycle, and
discontinued treatment.
In the overall series, seven complete responses (10.4%, 95% CI:
3.1–17.7) and 16 partial responses (23.9%, 95% CI: 13.7–34.1)
have been registered, with an overall response rate of 34.3% (95%
CI: 23.0–45.6). The median response duration was 22 weeks (range
4–85). Furthermore, 26 patients (38.8%, 95% CI: 27.1–50.5)
experienced a stabilisation of the disease (median duration: 36
weeks, range 18–87). A total of 18 (26.9%, 95% CI: 16.3–47.5)
progressed when on treatment. In the whole series, the median
time to progression was 28 weeks (range 4–97). Within the
resistant population, there were one complete and eight partial
responses for an overall response rate of 25% (95% CI : 10.9–39.1).
The median response duration was 18 weeks (range 4–50).
Stabilisation of the disease was observed in 13 out of 36 patients
(36.1%, 95% CI: 20.4–51.8) with a median duration of 36 weeks
(range 18–87).
Within the group of platinum-sensitive patients, there were six
complete and eight partial responses for an overall response rate of
45.2% (95% CI: 27.7–62.7). The median response duration was 28
weeks (range 4–85). Stabilisation of the disease was observed in 13
out of 31 patients (41.9%, 95% CI: 24.5–59.3) with a median
duration of 35 weeks (range 18–71).
Table 1 Patient characteristics
Characteristic No. %
Patients entered 70 100.0
Evaluable 67 95.7
Median age (range) (years) 59 (25–76)
Median performance status (range) 1 (0–2)
Platinum/paclitaxel resistant 38 54.3
Sensitive 32 45.7
No. of prior chemotherapy regimens
1 34 48.6
2 26 37.1
3 6 8.6
43 4 5.7
Liposomal doxorubicin and gemcitabine in ovarian cancer
G D’Agostino et al
1181
British Journal of Cancer (2003) 89(7), 1180–1184 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lToxicity
A total of 443 courses are evaluable for toxicity, a median number
of six cycles (range 1–13) having been administered per patient.
The mean dose of PLD administered per cycle to each patient was
29mgm
 2 (median: 30mgm
 2, range 25–30mgm
 2), whereas the
mean dose of GEM administered per cycle to each patient was
1932mgm
 2 (median: 2000mgm
 2, range 1520–2000mgm
 2).
A 20% dose reduction was required by 19 patients (27.1%), for a
total of 78 cycles (17.6%); a 1-week-delay was necessary for five
patients (7.1%) and a total of five cycles (1.1%). Seven patients
(10%) required discontinuation of treatment because of haemato-
logical toxicity (n¼3), palmar–plantar erythrodysesthesia (PPE)
(n¼1), gastrointestinal toxicity (n¼1) and mucositis (n¼2).
Discontinuation due to PPE occurred after the fourth cycle, while
in the other cases of nonhaematological toxicity, interruption
occurred at the end of the 10th, second, and fifth cycles,
respectively. In all, 15 patients (21.4%) (total number of cycles:
24, 5.4%) were unable to receive the day 8 GEM administration
because of haematological toxicity.
Severe haematological toxicity was registered in 30 patients
(42.8%, Table 3); in particular, anaemia: G3, 4.2%; G4, 2.8%;
neutropenia: G3, 27.1%; G4, 8.5%; thrombocytopenia: G3, 7.1%;
G4, 1.4%. Blood transfusions were required in two patients (2.8%),
and one of them was hospitalised because of severe fatigue. Eight
patients (11.4%) were treated with epoetin. The granulocyte-
colony stimulating factor (G-CSF), administered only in the case of
G4 neutropenia with fever or persisting more than 5 days, was
necessary for three patients (4.2%), and one of them was
hospitalised. Thrombocytopenia was never complicated by bleed-
ing episodes or platelet transfusion requirements.
The main nonhaematological toxicities are summarised in
Table 4: in no case did we observe grade 4 nonhaematologic
toxicities or cardiac adverse events. PPE affected 24 patients
(34.2%), but only in seven of them (10%) was it so heavy to
compromise the activities of the day-living and only one (1.4%)
required discontinuation of the therapy. Topic aloe-vera-based
compounds were used to treat PPE, whereas oral dexamethasone
(8mgdie
 1) was administered only to the patients with grade 3
cutaneous toxicity. Mild stomatitis (G1–G2) was observed in 15
patients (21.4%). Paresthesia was registered in a total of six
patients (8.5%). Nausea/vomiting was fully controlled by the
metoclopramide premedication, whereas alopecia was not evalu-
ated since the majority of the patients already presented with
alopecia at the enrollment because of the previous treatments;
anyway, it was not experienced de novo by any of the treated
patients.
DISCUSSION
We report herein the results of a phase II trial on the combination
of GEM and PLD in recurrent ovarian cancer patients. In the whole
series of patients, an overall response rate of 34.3% has been
registered, with complete responders amounting to 10.4%. These
findings are quite satisfying and confirm not only the encouraging
results of the phase I but even the preliminary results of the phase
II study recently presented at the 2002 ASCO meeting (D’Agostino
et al, 2002b). Moreover, these results seem to represent the best
response rates reported in the salvage treatment of ovarian cancer
with regimens not including platinum and/or taxanes (Bajetta et al,
1996; Rose et al, 1998; Gordon et al, 2001).
Within the subgroup of resistant patients, the overall response
rate of 25% is superior to the response rates of 18.3 and 12.3%
obtained with PLD alone in phase II and III trials (Gordon et al,
2000, 2001), respectively, and is even better than the results
obtained in several trials testing GEM in this clinical setting
(Markman, 2002). Although it is recognised that the direct
Table 2 Clinical response according to platinum sensitivity
Complete Partial Stable disease Progression
Platinum sensitivity Total No. % No % No. % No. %
Resistant 36 1 2.8 8 22.2 13 36.1 14 38.9
Sensitive 31 6 19.4 8 25.8 13 41.9 4 12.9
Total evaluable pts 67 7 10.4 16 23.9 26 38.8 18 26.9
Table 3 Haematological toxicity
Grade 3 Grade 4
Toxicity No. pts (%) No. cycles (%) No. pts (%) No. cycles (%)
Haemoglobin 3 (4.2) 3 (0.6) 2 (2.8) 2 (0.5)
Neutrophils 19 (27.1) 26 (5.8) 6 (8.5) 7 (1.5)
Platelets 5 (7.1) 6 (1.3) 1 (1.4) 1 (0.2)
Table 4 Nonhaematological toxicity
Grade 1 Grade 2 Grade 3
Toxicity No. pts (%) No. pts (%) No. pts (%)
PPE 6 8.5 11 15.7 7 10.0
Stomatitis 4 5.7 11 15.7 7 10.0
Paresthesia 3 4.2 2 2.8 1 1.4
Diarrhoea 5 7.1 3 4.2 1 1.4
Hepatic 2 2.8 3 4.2 0 0
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studies is difficult, it is also worth noting that the percentage of
stabilisation of the disease reported in the current study in the
overall series (38.8%) and especially in the subgroup of resistant
patients (36.1%) compare favourably to that reported by Gordon
et al (2001) using PLD and by Shapiro et al (1996) using single-
agent GEM.
The possibility to achieve a long-lasting disease stabilisation is
an important end point for patients whose life expectancy is
generally very poor, recent studies having demonstrated that the
survival benefit following second line chemotherapy, if a complete
remission is not obtained, is similar for partial responses and
stable diseases, and that the distinction between both could be
useless (Cesano et al, 1999).
Regarding the platinum-sensitive patients, we observed, as
expected compared with the resistant patients, a higher overall
response rate (45.2%), which is similar to the results obtained with
platinum rechallenge or other cytotoxic agents (Markman et al,
1991; Bookman, 1999; Zanotti et al, 2000; Cannistra, 2002) and
PLD, as previously reported (Gordon et al, 2001). This finding,
together with the documentation of 41.9% of disease stabilisation
in our series suggest that this drug combination might be of value
in recurrent ovarian cancer patients considered sensitive to first-
line platinum treatment. This issue seems quite intriguing in view
of the potential clinical value of using nonplatinum drugs to
prolong the platinum-free interval which is the most critical
predictor of sensitivity to platinum rechallenge, although con-
troversies still exist (Markman et al, 1991; Ozols, 1997; Bookman,
1999; Cannistra, 2002).
As far as the toxicity is concerned, the combination of GEM with
PLD in a 21-day-based schedule led neither to the reduction of the
mean (median) cumulative dose of PLD, which is quite comparable
to that administered with the standard 50mgm
 228-day cycle
 1
(Gordon et al, 2000; 2001), nor did it imply a decrease in the dose
intensity.
The proportion of patients experiencing G3/G4 neutropenia
(35.7%) was considerable, and notably higher than that reported
by using GEM or PLD alone; however, the rates of discontinuation,
delay, interruption of treatment due to haematological toxicity
were even lower than that reported in the above-mentioned studies
(Shapiro et al, 1996; Gordon et al, 2001). Moreover, haematological
toxicity was always easily managed and did not result in a larger
use of haematopoietic growth factors, or blood transfusions, when
compared with the regimens utilising PLD (50mgm
 2) in a 28-day
based schedule (Gordon et al, 2001).
Regarding nonhaematological toxicity, stomatitis and PPE were,
as expected, the most frequently observed adverse events. In
particular, PPE, which is the primary dose-limiting side effect of
PLD, occurred in a lower percentage of cases with respect to what
was reported by the main trials testing PLD (Gordon et al, 2000,
2001; Safra et al, 2001), requiring the discontinuation of treatment
in only 2.8% of cases. G3-G4 PPE, in fact, hit only 10% of patients
in our series, compared with 18, 17.3 and 23% registered in the
previously reported studies (Gordon et al, 2000, 2001; Safra et al,
2001), respectively.
A formal health-related quality of life research was not
performed in this trial; we do believe that a disability paradox
(Albrecht and Devlieger, 1999) may often induce the patients
enrolled in a phase II study to accommodate to their illness,
changing internal standards and values, and eventually over-
estimating the meaning of their self-evaluation of quality of life
(Sprangers and Schwartz, 1999); anyway, the fact that a total of 443
courses have been administered in an outpatient setting with full
compliance by the patients, who received a median number of six
cycles each, witnesses the safety of the treatment.
In conclusion, the combination of gemcitabine and PLD has
proved to be a valid approach in recurrent ovarian cancer
patients. In particular, in the subgroup of resistant patients the
overall response rate and, above all, the proportion of disease
stabilisation were encouraging. Furthermore, the results
reported in this study relaunch the option that a polychemother-
apy can offer better chances of response to fit patients even in the
salvage setting. In this context, in fact, some reports of high
response rates for drugs used in combination (Dizon et al,
2001) and the recent availability of less-toxic drugs and better
haematological supports make the use of combination chemother-
apy in recurrent ovarian cancer, a re-emerging challenging
issue.
Based on in vitro data suggesting a potential synergistic
interaction between the two drugs (Zoli et al, 1999; Chow et al,
2000), specific tests in preclinical models are ongoing in our
laboratories in order to analyse the antitumour activity of the
GEM/PLD combination and possibly clarify the underlying
mechanisms of drug interaction.
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